List view / Grid view
4 February 2021 | By Beckman Coulter Life Sciences
Learn how the Coulter Principle can precisely measure minute distributions of biological particles. This principle can be used to analyse cyanobacteria, E. coli bacteria, CHO cells, CAR T cells, yeast cells, algae cells, fat cells, plant cells and more.
The review will evaluate data from preclinical and clinical studies of NVX-CoV2373 to expedite the vaccine’s marketing authorisation approval later.
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
The UK Government has given £7 million of funding for a clinical trial which will investigate whether patients can be given different COVID-19 vaccines for each dose.
In this article, we investigate three of the latest developments in COVID-19 therapeutics that are delivered intranasally.
G-CON cleanroom PODs. Reliable, flexible prefabricated cleanrooms for the biopharmaceutical industry. On budget and on time.
Report finds 2020 was a record-breaking year for investment in UK biotech, driven by innovation and the COVID-19 pandemic, with growth anticipated to continue into 2021.
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803-300x278.jpg)
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803.jpg)
A preliminary analysis suggests the COVID-19 Vaccine AstraZeneca was 74 percent effective after the first dose and 82 percent effective with a 12-week inter-dose interval.
An interim analysis from a Phase III trial of the Sputnik V vaccine has shown it is effective against symptomatic COVID-19.
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and 85.6 percent effective against the B.1.1.7 SARS-CoV-2 variant, in a Phase III trial.
An interim analysis has shown that the COVID-19 vaccine developed by J&J is safe and effective at preventing the coronavirus in adults.
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
The UK Government has ordered a further 40 million doses of Valneva’s COVID-19 vaccine candidate, to be manufactured in Scotland.
